BOSTON, Massachusetts, USA, June 3, 2026
Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global research collaboration and licensing agreement to develop innovative RNA exon editing therapies for inherited kidney diseases, marking a significant advancement in the field of genetic medicine. Under the agreement, Lilly will gain exclusive rights to apply Ascidian’s proprietary RNA exon editing technology to undisclosed monogenic kidney disease targets, while retaining the option to expand the collaboration to additional programs in the future. The partnership has the potential to generate up to $1.9 billion in value for Ascidian through upfront payments, development milestones, commercial milestones, and royalties. The alliance combines Lilly’s growing leadership in genetic medicines with Ascidian’s breakthrough RNA rewriting platform, which is designed to repair disease-causing genetic instructions without altering the underlying DNA sequence.
RNA Exon Editing Opens New Possibilities for Genetic Kidney Diseases
Inherited kidney diseases affect millions of patients globally and often result from mutations in large or highly variable genes that remain difficult to address using existing gene therapy and gene-editing technologies. According to Ascidian, more than 60 known genetic diseases affect the kidneys, while over 3.5 million Americans live with severe inherited kidney disorders. The company’s RNA exon editing technology was developed specifically to overcome limitations associated with conventional genetic medicine approaches.
Unlike DNA-editing technologies that permanently alter the genome, Ascidian’s platform rewrites RNA by leveraging the cell’s natural RNA splicing machinery to repair faulty genetic instructions. The technology is capable of editing multiple whole exons at kilobase scale, enabling correction of large and complex mutations that are not easily addressed by current therapeutic methods. This capability could significantly expand treatment opportunities for patients suffering from previously untreatable genetic kidney diseases.
Lilly to Lead Clinical Development and Commercialization
Advertisement
Under the terms of the collaboration, Ascidian will be responsible for discovery activities and selected preclinical development efforts, while Lilly will oversee additional preclinical studies, clinical development, manufacturing, regulatory activities, and global commercialization. The structure allows each company to contribute its core expertise while accelerating the advancement of novel therapies toward patients. Lilly’s extensive experience in drug development and commercialization is expected to complement Ascidian’s innovative RNA biology platform and scientific expertise.
Importantly, Ascidian retains the ability to pursue additional kidney disease targets independently or through future partnerships, preserving flexibility for continued expansion of its broader research pipeline. The agreement reflects increasing pharmaceutical industry interest in RNA-based therapeutics, which are emerging as one of the most promising areas of next-generation precision medicine.
Strategic Alliance Strengthens Future of RNA Medicines
The collaboration represents a major validation of RNA exon editing as a potentially transformative therapeutic modality. Ascidian believes its platform can deliver the durability traditionally associated with gene therapy while reducing many of the risks linked to permanent DNA modification and gene replacement technologies. By restoring the production of full-length functional proteins through precise RNA editing, the company aims to provide long-lasting treatment benefits from a single administration.
Industry observers view the partnership as an important milestone in the evolution of genetic medicine, particularly for diseases driven by complex mutations that have remained beyond the reach of existing technologies. The substantial financial commitment from Lilly further underscores confidence in the platform’s scientific potential and commercial prospects. As research in RNA therapeutics continues to accelerate, the collaboration could help establish a new treatment paradigm for inherited kidney disorders while expanding the role of RNA editing technologies across a broader range of genetic diseases in the future.
Source: Ascidian Therapeutics, Eli Lilly press release
